Abstracts

Incidental Carotid Plaque in HIV is Associated With Subsequent Cerebrovascular Events

Coronary atherosclerotic plaque is increased in HIV-infected individuals and associated with subsequent cardiovascular events. Cerebrovascular (CV) events including stroke and transient ischemic attack (TIA) are also increased in HIV; however there are no data characterizing the prevalence, characteristics and prognostic associations of incidental carotid plaque in HIV.   From a registry, we identified all HIV-infected…

Distinct Gut Microbiota Composition in Gay Men

The precise effects of HIV-1 on the human microbiome are unclear. Initial cross-sectional studies provided contradictory associations between microbial richness and HIV status and suggested shifts from Bacteroides to Prevotella predominance following HIV-1 infection, which have not been found in animal models or in studies matched for HIV-1 risk groups. This was a cross-sectional study…

Enhancement of Microbiota in Macaques Leads to Beneficial Immune Function Modulation

With more than thirty million HIV-infected individuals worldwide, developing an effective vaccine to prevent new HIV infections remains a top priority in contemporary biomedical research. Given the critical role of mucosal surfaces in susceptibility to HIV, it is imperative that we induce effective mucosal responses. However, current approaches to enhance mucosal immunity have not been…

Fecal Microbial Transplantation: Safety and Engraftment During Treated HIV Infection

Despite antiretroviral therapy (ART), a substantial number of HIV-infected individuals exhibit chronic systemic inflammation. Many treated HIV-infected individuals exhibit marked alterations in the gut microbiome, and the degree of dysbiosis correlates positively with plasma markers of inflammation. Whether interventions to modulate the microbiome can affect systemic inflammation is not known. A single-arm colonoscopically delivered fecal…

Nevirapine (NVP) Concentrations in HIV-Infected Newborns Receiving Therapeutic Dosing

Very early antiretroviral treatment (ART) initiation in HIV infected newborns may limit the seeding of viral reservoirs and maintain immune responses, but few antiretroviral agents are approved for use in newborns. Prophylactic NVP dosing is well established, but the appropriate NVP dose for treatment, which requires higher NVP levels than prophylaxis, is still unknown.  While…

Pharmacokinetics, Safety, and Efficacy of Maraviroc in Pediatric Patients With R5 HIV

Maraviroc (MVC) is a CCR5 antagonist approved to treat adults infected with CCR5-tropic (R5) HIV-1. Study A4001031 was conducted to evaluate the pharmacokinetics (PK), safety and efficacy of MVC in treatment-experienced (TE) pediatric patients. This is an open-label, two-stage (stage 1: dose-finding; stage 2: safety/efficacy), age-stratified, non-comparative, multicenter study to evaluate the PK, safety and…